Originally published as JCO Early Release 10.1200/JCO.2006.07.5390 on December 4 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loprinzi, C. L. Articles by Jaslowski, A. J. Search for Related Content PubMed PubMed Citation Articles by Loprinzi, C. L. Articles by Jaslowski, A. J.

Phase III Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone: NCCTG N03C5

Charles L. Loprinzi, John W. Kugler, Debra L. Barton, Amylou C. Dueck, Loren K. Tschetter, Robert A. Nelimark, Ernie Porteza Balcueva, Kelli N. Burger, Paul J. Novotny, Mark D. Carlson, Steven Fletcher Duane, Steven W. Corso, David B. Johnson, Anthony J. Jaslowski

From the Mayo Clinic, Rochester; Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; Illinois Oncology Research Association Community Clinical Oncology Program (CCOP), Peoria, IL; Cancer Consortium, Sioux Falls, SD; Michigan Cancer Consortium, Ann Arbor, MI; Missouri Valley Cancer Consortium, Omaha, NE; Upstate Carolina CCOP, Spartanburg, SC; Wichita Community Clinical Oncology Program, Wichita, KS; and the St Vincent Regional Cancer Center CCOP, Green Bay, WI.

Address reprint requests to Charles L. Loprinzi, MD, Mayo Clinic, 200 First St, SW, Rochester, MN 55905; e-mail: cloprinzi{at}mayo.edu

PURPOSE: Despite the utility of newer antidepressants for alleviating hot flashes, antidepressants do not work adequately enough in many patients. Gabapentin is a nonhormonal agent that also can reduce hot flashes. No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash control with an antidepressant alone.

PATIENTS AND METHODS: This was a randomized trial in which 118 patients with inadequate hot flash control on an antidepressant were randomly assigned to receive both an antidepressant and gabapentin versus being weaned off the antidepressant and receiving gabapentin alone. Patients were observed for 5 weeks (including a baseline week in which patients continued on their current antidepressant without gabapentin) during which time they completed validated daily hot flash diaries.

RESULTS: Ninety-one patients provided complete data at the 5-week assessment. Regardless of whether or not the antidepressant was continued when gabapentin was started, there was an approximately 50% median reduction in hot flash frequencies (54%; 95% CI, 34% to 70% for combined treatment v 49%; 95% CI, 26% to 58% for gabapentin alone) and scores (56%; 95% CI, 26% to 71% for combined treatment v 60%; 95% CI, 33% to 73% for gabapentin alone).

CONCLUSION: Gabapentin seems to decrease hot flashes by approximately 50% in women with inadequate hot flash control who were using an antidepressant. This study saw no significant additional hot flash reduction from continuation of the antidepressant.

published online ahead of print at www.jco.org on December 4, 2006.

Supported in part by Public Health Service Grants No. CA-25224, CA-37404, CA-35103, CA-35103, CA-63848, CA-63849, CA-35267, CA-35113, CA-35119, CA-35431, CA-35195, CA-35101, CA-37417, and CA-35090.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				Managing Hot Flashes in Women with Breast Cancer Journal Watch Oncology and Hematology, February 12, 2007; 2007(212): 5 - 5. [Full Text]